PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
18.78%
Revenue growth 1.25-1.5x CRON.TO's 14.92%. Bruce Berkowitz would check if differentiation or pricing power justifies outperformance.
49.59%
Gross profit growth similar to CRON.TO's 47.95%. Walter Schloss would assume both firms track common industry trends.
190.40%
EBIT growth 1.25-1.5x CRON.TO's 165.12%. Bruce Berkowitz would verify if strategic initiatives are driving this edge.
190.40%
Positive operating income growth while CRON.TO is negative. John Neff might view this as a competitive edge in operations.
171.27%
Net income growth comparable to CRON.TO's 164.97%. Walter Schloss might see both following similar market or cost trajectories.
162.90%
EPS growth similar to CRON.TO's 164.52%. Walter Schloss would assume both have parallel share structures and profit trends.
162.90%
Similar diluted EPS growth to CRON.TO's 158.06%. Walter Schloss might see standard sector or cyclical influences on both firms.
2.26%
Share count expansion well above CRON.TO's 1.03%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
2.43%
Diluted share count expanding well above CRON.TO's 0.35%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-28.58%
Negative OCF growth while CRON.TO is at 28.21%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-32.85%
Negative FCF growth while CRON.TO is at 23.59%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
1211.10%
5Y CAGR of 1211.10% while CRON.TO is zero. Bruce Berkowitz would see if small improvements can scale into a larger advantage.
736.04%
3Y revenue/share CAGR above 1.5x CRON.TO's 312.96%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
-600.11%
Negative 10Y OCF/share CAGR while CRON.TO stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-3629.51%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-19942.46%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
175.53%
10Y net income/share CAGR of 175.53% while CRON.TO is zero. Bruce Berkowitz would see if minor gains can compound into a bigger lead over time.
37300.27%
5Y net income/share CAGR above 1.5x CRON.TO's 1977.71%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
-73.74%
Negative 3Y CAGR while CRON.TO is 2927.29%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
4319.20%
Equity/share CAGR of 4319.20% while CRON.TO is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
1522.06%
Below 50% of CRON.TO's 3147.81%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
48.90%
Below 50% of CRON.TO's 1150.37%. Michael Burry suspects a serious short-term disadvantage in building book value.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.05%
AR growth is negative/stable vs. CRON.TO's 38.65%, indicating tighter credit discipline. David Dodd confirms it doesn't hamper actual sales.
47.19%
Inventory growth well above CRON.TO's 5.91%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
3.70%
Asset growth above 1.5x CRON.TO's 0.45%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
3.02%
50-75% of CRON.TO's 5.02%. Martin Whitman suspects weaker earnings or capital allocation vs. the competitor.
-4.80%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
4.80%
R&D dropping or stable vs. CRON.TO's 30.38%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
0.20%
SG&A declining or stable vs. CRON.TO's 23.74%. David Dodd sees better overhead efficiency if it doesn't hamper revenue.